Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Travere Therapeutics Inc.

    NASDAQ: TVTX · Real-Time Price · USD
    14.73
    0.23 (1.59%)
    At close: Jun 16, 2025, 3:59 PM
    14.89
    1.05%
    Pre-market: Jun 17, 2025, 07:03 AM EDT

    Travere Therapeutics Statistics

    Share Statistics

    Travere Therapeutics has 88.8M shares outstanding. The number of shares has increased by 16.57% in one year.

    Shares Outstanding

    n/a
    		 88.8M

    Shares Change (YoY)

    n/a
    		 16.57%

    Shares Change (QoQ)

    n/a
    		 1.96%

    Owned by Institutions (%)

    n/a
    		 99.99%

    Shares Floating

    n/a
    		 87.5M

    Failed to Deliver (FTD) Shares

    n/a
    		 395

    FTD / Avg. Volume

    n/a
    		 0.02%

    Short Selling Information

    The latest short interest is 12.5M, so 14.09% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 12.5M

    Short % of Shares Out

    n/a
    		 14.09%

    Short % of Float

    n/a
    		 15.58%

    Short Ratio (days to cover)

    n/a
    		 5.82

    Valuation Ratios

    The PE ratio is -4.27 and the forward PE ratio is 28.98. Travere Therapeutics's PEG ratio is -0.02.

    PE Ratio

    n/a
    		 -4.27

    Forward PE

    n/a
    		 28.98

    PS Ratio

    n/a
    		 5.89

    Forward PS

    n/a
    		 1.2

    PB Ratio

    n/a
    		 23.26

    P/FCF Ratio

    n/a
    		 -4.06

    PEG Ratio

    n/a
    		 -0.02
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Travere Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 2.08, with a Debt / Equity ratio of 6.8.

    Current Ratio

    n/a
    		 2.08

    Quick Ratio

    n/a
    		 2.04

    Debt / Equity

    n/a
    		 6.8

    Debt / EBITDA

    n/a
    		 -1.51

    Debt / FCF

    n/a
    		 -1.19

    Interest Coverage

    n/a
    		 -28.67

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $605,649.35

    Profits Per Employee

    n/a
    		 $-835,181.82

    Employee Count

    n/a
    		 385

    Asset Turnover

    n/a
    		 0.39

    Inventory Turnover

    n/a
    		 1.25

    Taxes

    Income Tax

    n/a
    		 120K

    Effective Tax Rate

    n/a
    		 -0.04%

    Stock Price Statistics

    The stock price has increased by 100.95% in the last 52 weeks. The beta is 0.74, so Travere Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.74

    52-Week Price Change

    n/a
    		 100.95%

    50-Day Moving Average

    n/a
    		 16.87

    200-Day Moving Average

    n/a
    		 17.69

    Relative Strength Index (RSI)

    n/a
    		 39.36

    Average Volume (20 Days)

    n/a
    		 1,795,393

    Income Statement

    In the last 12 months, Travere Therapeutics had revenue of 233.18M and earned -321.55M in profits. Earnings per share was -4.08.

    Revenue

    n/a
    		 233.18M

    Gross Profit

    n/a
    		 225.43M

    Operating Income

    n/a
    		 -320.63M

    Net Income

    n/a
    		 -321.55M

    EBITDA

    n/a
    		 -265.77M

    EBIT

    n/a
    		 -309.33M

    Earnings Per Share (EPS)

    n/a
    		 -4.08
    Full Income Statement

    Balance Sheet

    The company has 58.53M in cash and 401.58M in debt, giving a net cash position of -343.05M.

    Cash & Cash Equivalents

    n/a
    		 58.53M

    Total Debt

    n/a
    		 401.58M

    Net Cash

    n/a
    		 -343.05M

    Retained Earnings

    n/a
    		 -1.45B

    Total Assets

    n/a
    		 548.8M

    Working Capital

    n/a
    		 191.71M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -237.47M and capital expenditures -101.21M, giving a free cash flow of -338.69M.

    Operating Cash Flow

    n/a
    		 -237.47M

    Capital Expenditures

    n/a
    		 -101.21M

    Free Cash Flow

    n/a
    		 -338.69M

    FCF Per Share

    n/a
    		 -4.29
    Full Cash Flow Statement

    Margins

    Gross margin is 96.68%, with operating and profit margins of -137.51% and -137.9%.

    Gross Margin

    n/a
    		 96.68%

    Operating Margin

    n/a
    		 -137.51%

    Pretax Margin

    n/a
    		 -137.45%

    Profit Margin

    n/a
    		 -137.9%

    EBITDA Margin

    n/a
    		 -113.98%

    EBIT Margin

    n/a
    		 -137.51%

    FCF Margin

    n/a
    		 -145.25%

    Dividends & Yields

    TVTX does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for TVTX is $31.5, which is 113.8% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $31.5

    Price Target Difference

    n/a
    		 113.8%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 15
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Stock Splits

    The last stock split was on Nov 2, 2012. It was a backward split with a ratio of 1:9.

    Last Split Date

    n/a
    		 Nov 2, 2012

    Split Type

    n/a
    		 backward

    Split Ratio

    n/a
    		 1:9

    Scores

    Altman Z-Score

    n/a
    		 -2.58

    Piotroski F-Score

    n/a
    		 3

    Add to Watchlist